Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Expected to Announce Earnings of $0.09 Per Share

Brokerages expect Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to announce $0.09 earnings per share for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Ironwood Pharmaceuticals’ earnings, with estimates ranging from $0.03 to $0.12. Ironwood Pharmaceuticals posted earnings of ($0.38) per share in the same quarter last year, which would suggest a positive year over year growth rate of 123.7%. The firm is scheduled to announce its next earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Ironwood Pharmaceuticals will report full year earnings of ($0.08) per share for the current year, with EPS estimates ranging from ($0.26) to $0.01. For the next fiscal year, analysts anticipate that the business will post earnings of $0.52 per share, with EPS estimates ranging from $0.18 to $1.08. Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.15. The firm had revenue of $102.22 million for the quarter, compared to the consensus estimate of $89.28 million. The company’s revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.22) EPS.



A number of research analysts have issued reports on IRWD shares. BidaskClub lowered shares of Ironwood Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 11th. Credit Suisse Group restated a “neutral” rating on shares of Ironwood Pharmaceuticals in a research note on Wednesday, July 10th. HC Wainwright set a $13.00 price target on shares of Ironwood Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, June 24th. Cowen set a $12.00 price target on shares of Ironwood Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, September 13th. Finally, ValuEngine upgraded shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $14.86.

In other news, President Thomas A. Mccourt sold 220,000 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $9.24, for a total value of $2,032,800.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Halley E. Gilbert sold 20,000 shares of the company’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $10.00, for a total transaction of $200,000.00. The disclosure for this sale can be found here. Insiders sold a total of 240,212 shares of company stock worth $2,234,716 over the last ninety days. Insiders own 5.90% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in IRWD. Macquarie Group Ltd. purchased a new stake in Ironwood Pharmaceuticals during the second quarter worth $1,295,000. United Services Automobile Association boosted its holdings in Ironwood Pharmaceuticals by 3.9% during the second quarter. United Services Automobile Association now owns 225,058 shares of the biotechnology company’s stock worth $2,462,000 after buying an additional 8,500 shares in the last quarter. ClariVest Asset Management LLC purchased a new stake in Ironwood Pharmaceuticals during the second quarter worth $1,455,000. Nuveen Asset Management LLC purchased a new stake in Ironwood Pharmaceuticals during the second quarter worth $10,126,000. Finally, AQR Capital Management LLC boosted its holdings in Ironwood Pharmaceuticals by 181.9% during the second quarter. AQR Capital Management LLC now owns 149,888 shares of the biotechnology company’s stock worth $1,640,000 after buying an additional 96,719 shares in the last quarter.

Shares of NASDAQ IRWD traded down $0.19 during trading hours on Friday, hitting $8.85. 32,678 shares of the stock were exchanged, compared to its average volume of 2,218,924. Ironwood Pharmaceuticals has a 12 month low of $8.40 and a 12 month high of $19.36. The company has a market cap of $1.48 billion, a PE ratio of -9.36 and a beta of 1.79. The firm has a fifty day moving average price of $9.27 and a 200-day moving average price of $10.91.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Read More: How to interpret Moving Average Convergence Divergence (MACD)

Get a free copy of the Zacks research report on Ironwood Pharmaceuticals (IRWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.